Francisco Ballester to retire; Peter Stenico appointed President Region International
Sandoz, the global leader in generic and biosimilar medicines, has announced key leadership changes. Francisco Ballester, President Region International and Executive Committee member, will retire on March 1, 2025, after 34 years of service. Peter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, will succeed Ballester as President Region International and join the Sandoz Executive Committee.
Ballester has been responsible since 2019 for driving business growth and access in markets outside North America and Europe. Stenico, who joined Sandoz in 2002, brings extensive experience in biosimilars and generics through various strategic, M&A, and commercial roles. He previously served as Country Head for Sandoz Germany and President of the German Generics Association.
Sandoz, il leader globale nei farmaci generici e biosimilari, ha annunciato importanti cambiamenti nella leadership. Francisco Ballester, Presidente della Regione Internazionale e membro del Comitato Esecutivo, andrà in pensione il 1° marzo 2025, dopo 34 anni di servizio. Peter Stenico, attualmente Responsabile della Piattaforma Globale Biosimilari e Presidente di Sandoz Austria, succederà a Ballester come Presidente della Regione Internazionale e entrerà nel Comitato Esecutivo di Sandoz.
Ballester è stato responsabile dal 2019 per la crescita del business e l'accesso ai mercati al di fuori del Nord America e dell'Europa. Stenico, che è entrato in Sandoz nel 2002, porta con sé una vasta esperienza nel campo dei biosimilari e dei generici attraverso vari ruoli strategici, di fusioni e acquisizioni e commerciali. Ha precedentemente ricoperto il ruolo di Responsabile Nazionale per Sandoz Germania e Presidente dell'Associazione Tedesca dei Generici.
Sandoz, el líder mundial en medicamentos genéricos y biosimilares, ha anunciado cambios clave en su liderazgo. Francisco Ballester, Presidente de la Región Internacional y miembro del Comité Ejecutivo, se jubilará el 1 de marzo de 2025, después de 34 años de servicio. Peter Stenico, actual Jefe Global de Plataforma de Biosimilares y Presidente de Sandoz Austria, sucederá a Ballester como Presidente de la Región Internacional y se unirá al Comité Ejecutivo de Sandoz.
Ballester ha sido responsable desde 2019 de impulsar el crecimiento del negocio y el acceso a los mercados fuera de América del Norte y Europa. Stenico, quien se unió a Sandoz en 2002, aporta una amplia experiencia en biosimilares y genéricos a través de diversos roles estratégicos, de fusiones y adquisiciones, y comerciales. Anteriormente, sirvió como Jefe Nacional de Sandoz Alemania y Presidente de la Asociación Alemana de Genéricos.
산도즈, 제네릭 및 바이오시밀러 의약품의 글로벌 리더,가 주요 리더십 변화를 발표했습니다. 프란시스코 발레스터, 국제 지역 회장 및 집행 위원회 멤버가 34 년간의 근무 후 2025년 3월 1일 은퇴합니다. 피터 스테니코, 현재 글로벌 플랫폼 바이오시밀러 책임자이자 산도즈 오스트리아의 국가 회장이 발레스터를 이어 국제 지역 회장직을 맡으며 산도즈 집행 위원회에 합류합니다.
발레스터는 2019년 이후 북미 및 유럽 외 시장에서 비즈니스 성장 및 접근성을 확대하는 책임을 맡아왔습니다. 2002년 산도즈에 합류한 스테니코는 다양한 전략적, 인수 합병 및 상업적 역할을 통해 바이오시밀러 및 제네릭 분야에서 폭넓은 경험을 제공합니다. 이전에는 산도즈 독일의 국가 책임자이자 독일 제네릭 협회의 회장을 역임했습니다.
Sandoz, le leader mondial des médicaments génériques et biosimilaires, a annoncé des changements clés dans sa direction. Francisco Ballester, Président de la Région Internationale et membre du Comité Exécutif, prendra sa retraite le 1er mars 2025 après 34 ans de service. Peter Stenico, actuellement Responsable de la Plateforme Globale des Biosimilaires et Président de Sandoz Autriche, succédera à Ballester en tant que Président de la Région Internationale et rejoindra le Comité Exécutif de Sandoz.
Ballester est responsable depuis 2019 de la croissance des affaires et de l'accès aux marchés en dehors de l'Amérique du Nord et de l'Europe. Stenico, qui a rejoint Sandoz en 2002, apporte une vaste expérience dans le domaine des biosimilaires et des génériques grâce à divers rôles stratégiques, de fusions et acquisitions, et commerciaux. Il a précédemment été Responsable National pour Sandoz Allemagne et Président de l'Association Allemande des Génériques.
Sandoz, der globale Marktführer im Bereich generischer und biosimilarer Arzneimittel, hat wichtige Veränderungen in der Führung angekündigt. Francisco Ballester, Präsident der Region International und Mitglied des Exekutivkomitees, wird nach 34 Jahren im Dienst am 1. März 2025 in den Ruhestand gehen. Peter Stenico, derzeit Leiter der globalen Plattform für Biosimilars und Landespräsident von Sandoz Österreich, wird Ballester als Präsident der Region International nachfolgen und dem Exekutivkomitee von Sandoz beitreten.
Ballester war seit 2019 verantwortlich für das Wachstum des Geschäfts und den Zugang zu Märkten außerhalb von Nordamerika und Europa. Stenico, der 2002 zu Sandoz kam, bringt umfassende Erfahrung im Bereich Biosimilars und Generika durch verschiedene strategische, M&A- und kommerzielle Rollen mit. Zuvor war er Landesleiter von Sandoz Deutschland und Präsident des deutschen Generika-Verbandes.
- None.
- None.
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
- President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service
- Peter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee
Basel, February 3, 2025 – Sandoz, the global leader in generic and biosimilar medicines, announced today that Francisco Ballester, President Region International and member of the Sandoz Executive Committee, will retire and step down from the SEC on March 1, 2025. Since 2019, Francisco has been responsible in this role for driving business growth and access for patients in markets outside of North America and Europe, while developing highly diverse talents in the region. He is a member of the Health Management and Policy Advisory Council of the Miami Herbert Business School.
Drawing on a strong bench of internal leaders, Peter Stenico will succeed Francisco. Peter was appointed Global Platform Head, Biosimilars in January 2023 and has led the Sandoz global biosimilar strategy. Previously, Peter held the position of Country Head and General Manager for Sandoz in Germany and was also the former President of the German Generics Association (Pro Generika). Peter joined Sandoz in 2002 and has gained vast biosimilars and generics industry experience through various roles covering strategy, M&A and commercial at global, regional and local levels.
Richard Saynor, Chief Executive Officer of Sandoz, said: “It is not every day we can recognize a colleague who has devoted virtually his entire career to our company. Francisco spent over three decades taking on diverse and increasingly more senior roles at the organization, demonstrating focus, passion, and dedication to the business and our people. I am personally grateful for his many contributions and insights we have worked together on the Sandoz Executive Committee. I wish Francisco all the very best for his retirement.
I am immensely proud of the huge wealth of experience we have at Sandoz. Like Francisco, Peter can look back on a successful career of many decades at Sandoz and he will bring this extensive experience to his new role and to the Sandoz Executive Committee. I welcome him to the team and wish him much success in taking Sandoz Region International to the next level of growth.”
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion.
CONTACTS
| Global Media Relations contacts | Investor Relations contacts |
| Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
| Joerg E. Allgaeuer +49 171 838 4838 | Craig Marks +44 7818 942 383 |
Attachment
FAQ
When will Francisco Ballester retire from his position at Sandoz (SDZNY)?
Who will replace Francisco Ballester as President Region International at Sandoz (SDZNY)?
What is Peter Stenico's current role at Sandoz (SDZNY)?
How long has Francisco Ballester worked at Sandoz (SDZNY)?
